➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
AstraZeneca
Moodys
Boehringer Ingelheim
McKesson

Last Updated: August 10, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ARISTADA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for ARISTADA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01469039 A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia Completed Alkermes, Inc. Phase 3 2011-12-01 The study will determine the efficacy of ALKS 9072 (also known as aripiprazole lauroxil or ALKS 9070) for the treatment of schizophrenia in subjects experiencing an acute exacerbation.
NCT02634320 A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia Recruiting Alkermes, Inc. Phase 4 2015-12-01 This study will evaluate the safety and tolerability of aripiprazole lauroxil (also known as ARISTADA, ALKS 9070).
NCT03345979 A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia Not yet recruiting Alkermes, Inc. Phase 3 2017-11-01 This study will evaluate the efficacy of initiating treatment of schizophrenia with an investigational product followed by a 2-month dose of AL.
NCT04203056 Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode Recruiting Alkermes, Inc. Phase 4 2019-12-16 This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
NCT04203056 Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode Recruiting University of California, Los Angeles Phase 4 2019-12-16 This 12-month study will evaluate the efficacy of aripiprazole lauroxil compared to oral aripiprazole in preventing the re-emergence of psychotic symptoms in patients with a recent onset of schizophrenia.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ARISTADA

Condition Name

Condition Name for ARISTADA
Intervention Trials
Schizophrenia 4
Schizophreniform Disorder 1
Schizoaffective Disorder, Depressive Type 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for ARISTADA
Intervention Trials
Schizophrenia 4
Psychotic Disorders 1
Disease 1
Depressive Disorder 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for ARISTADA

Trials by Country

Trials by Country for ARISTADA
Location Trials
United States 23
Russian Federation 5
Ukraine 2
Romania 2
Philippines 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for ARISTADA
Location Trials
Texas 3
California 3
Missouri 2
Illinois 2
Arkansas 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for ARISTADA

Clinical Trial Phase

Clinical Trial Phase for ARISTADA
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for ARISTADA
Clinical Trial Phase Trials
Recruiting 2
Completed 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for ARISTADA

Sponsor Name

Sponsor Name for ARISTADA
Sponsor Trials
Alkermes, Inc. 4
University of California, Los Angeles 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for ARISTADA
Sponsor Trials
Industry 4
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Colorcon
McKinsey
Mallinckrodt
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.